Blockade of Cannabinoid Type 1 Receptors Augments the Antiparkinsonian Action of Levodopa without Affecting Dyskinesias in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Treated Rhesus Monkeys
Xuebing Cao(Union Hospital), Stella M. Papa(Emory University), John R. Hadcock, Philip A. Iredale, Stewart A. Factor(Parkinson's and Movement Disorder Institute), Frank S. Menniti(Northwestern University), David A. Griffith, Liang Li, J. Timothy Greenamyre(University of Pittsburgh)
Cited by 101
Related Papers
The Parkinson Progression Marker Initiative (PPMI)
|Progress in Neurobiology|2011|1.9k
A highly reproducible rotenone model of Parkinson's disease
|Neurobiology of Disease|2009|791
Structure, Function, and Pharmacology of Glutamate Receptor Ion Channels
|Pharmacological Reviews|2021|676
Comprehensive Research Synopsis and Systematic Meta-Analyses in Parkinson's Disease Genetics: The PDGene Database
|PLoS Genetics|2012|543
Cerebrotendinous xanthomatosis: a comprehensive review of pathogenesis, clinical manifestations, diagnosis, and management
|Orphanet Journal of Rare Diseases|2014|315